Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Wrong vaccine; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a elderly patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) for prophylaxis. Co-suspect products included INFLUENZA VACCINE INACT SAG 3V (FLUAD) for prophylaxis. On an unknown date, the patient received FluLaval 2024-2025 season and did not receive FLUAD. On an unknown date, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced wrong vaccine administered (Verbatim: Wrong vaccine). The outcome of the wrong vaccine administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-SEP-2025 The Nurse Educator reported that an employee had administered FluLaval to a patient aged over 65 years. It was noted that Fluad is the recommended influenza vaccine for individuals in this age group due to its enhanced immunogenicity. During a call, the second line agent confirmed that the incident occurred because the patient had initially planned to receive a high-dose influenza vaccine. However, upon further probing, it was clarified that the administration of FluLaval was erroneous and not aligned with the intended vaccine choice.